Orchestra BioMed Holdings, Inc. (OBIO) - Dilution Analysis

10-Q filing | 62.7M shares outstanding

10-K filing | 38.2M shares outstanding

10-Q filing | 52.2M shares outstanding

8-K filing: Orchestra BioMed Holdings, Inc. entered into a stock purchase agreement with Terumo Medical Corporation, where Terumo agreed to purchase 200,000 shares of the Company's Series A Convertible Preferred Stock at $100.00 per share, for gross proceeds of $20.0 million. ($20.0M proceeds)

10-Q filing | 54.0M shares outstanding

8-K filing: Orchestra BioMed Holdings, Inc. entered into a revenue participation right purchase and sale agreement with Ligand Pharmaceuticals Incorporated for $35.0 million, issued a warrant to purchase up to 2,000,000 shares of common stock to Ligand, and Medtronic agreed to extend a convertible loan to the Company in the aggregate original principal amount of $20.0 million.

10-Q filing | 38.2M shares outstanding

10-K filing | 36.8M shares outstanding

10-Q filing | 37.6M shares outstanding

10-Q filing | 35.8M shares outstanding

S-3 filing: Orchestra BioMed Holdings, Inc. files an S-3 form to offer and sell up to $300,000,000 in various securities, including common stock, preferred stock, and debt securities, from time to time in one or more offerings and a separate offering of common stock having an aggregate offering price of up to $100,000,000 in an at-the-market offering through Jefferies.

10-Q filing | 35.8M shares outstanding

S-3/A filing: This S-3/A filing registers for resale shares of common stock and warrants by selling securityholders and also covers the issuance of common stock upon exercise of outstanding warrants.

10-K filing | 20.2M shares outstanding

S-3/A filing: This S-3/A filing relates to the offering of common stock issuable upon the exercise of outstanding warrants, including HSAC2 Warrants, Officer and Director Warrants, and Orchestra Warrants, by Orchestra BioMed Holdings, Inc.

10-Q filing | 20.2M shares outstanding

S-1 filing: This S-1 filing registers the issuance of up to 1,932,841 shares of common stock upon the exercise of warrants, as well as the resale of up to 22,221,440 shares of common stock and 750,000 warrants by selling securityholders.

10-Q filing | 20.2M shares outstanding

10-Q filing | 35.8M shares outstanding

10-K filing | 11.2M shares outstanding

8-K filing: Health Sciences Acquisitions Corporation 2 (HSAC2) received redemption requests for 1,597,888 ordinary shares in connection with the upcoming General Meeting on January 24, 2023, to vote on the business combination with Orchestra BioMed, Inc.

10-Q filing | 11.2M shares outstanding

10-Q filing | 11.2M shares outstanding

8-K filing: RTW Funds purchased 1,000,000 HSAC2 ordinary shares at $10.01 per share in a privately negotiated transaction from an accredited investor to fulfill obligations under a Forward Purchase Agreement and ensure shares were not redeemed. ($10.01M proceeds)

10-Q filing | 20.5M shares outstanding

10-K filing | 20.5M shares outstanding

10-Q filing | 20.5M shares outstanding

10-Q filing | 20.5M shares outstanding

10-Q filing | 20.5M shares outstanding

10-K filing | 20.5M shares outstanding

10-Q filing | 20.5M shares outstanding

8-K filing: Health Sciences Acquisitions Corporation 2 consummated the IPO of 16,000,000 ordinary shares at $10.00 per share, generating gross proceeds of $160,000,000. ($160.0M proceeds)

8-K filing: Health Sciences Acquisitions Corporation 2 consummated an IPO of 16,000,000 ordinary shares at $10.00 per share and a private placement with HSAC 2 Holdings, LLC of 450,000 ordinary shares and 1,500,000 warrants. ($172.0M proceeds)

S-1/A filing: S-1/A filing details the payment and delivery terms for firm securities, with a proposed amount of $125,000,000 ($143,750,000 if over-allotment option is exercised) at $10.00 per security.

S-1 filing: Health Sciences Acquisitions Corporation 2 is offering 12,500,000 ordinary shares at a price of $10.00 per share in an initial public offering.